EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine‐induced hepatic steatosis via both receptor‐dependent and receptor‐independent pathways

Piaopiao Huang iD, Juanli Ran iD, Wenqiang Zhu iD, Wen Dai iD, Yaxin Tang iD, Pingan Lian iD, Xiansheng Huang iD, Rong Li iD

The FASEB Journal · 2024

DOI: 10.1096/fj.202301748r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Piaopiao Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation, Natural Science Foundation of Hunan Province, Chinese Cardiovascular Association-Access.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schizophrenia, affecting approximately 1% of the global population, is often treated with olanzapine. Despite its efficacy, olanzapine's prolonged use has been associated with an increased risk of cardiovascular diseases and nonalcoholic fatty liver disease (NAFLD); however, the underlying mechanism remains unclear. Proprotein convertase subtilisin kexin type 9 (PCSK9) plays a crucial role in lipid metabolism and is involved in NAFLD pathogenesis via an unknown mechanism. This study aims to investigate the role of PCSK9 in olanzapine‐induced NAFLD. C57BL/6J mice and HepG2 and AML12 cell lines were treated with varying concentrations of olanzapine to examine the effects of olanzapine on PCSK9 and lipid metabolism. PCSK9 levels were manipulated using recombinant proteins, plasmids, and small interfering RNAs in vitro, and the effects on hepatic lipid accumulation and gene expression related to lipid metabolism were assessed. Olanzapine treatment significantly increased PCSK9 levels in both animal and cell line models, correlating with elevated lipid accumulation. PCSK9 manipulation demonstrated its central role in mediating hepatic steatosis through both receptor‐dependent pathways (impacting NPC1L1) and receptor‐independent pathways (affecting lipid synthesis, uptake, and cholesterol biosynthesis). Interestingly, upregulation of SREBP‐1c, rather than SREBP‐2, was identified as a key driver of PCSK9 increase in olanzapine‐induced NAFLD. Our findings establish PCSK9 as a pivotal factor in olanzapine‐induced NAFLD, influencing both receptor‐related and metabolic pathways. This highlights PCSK9 inhibitors as potential therapeutic agents for managing NAFLD in schizophrenia patients treated with olanzapine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9Non-alcoholic Fatty Liver DiseaseHumansMiceAnimalsMice, Inbred C57BLOlanzapineLipid MetabolismHomeostasisTriglyceridesCholesterolLipids

Stichwörter der Autor:innen

cholesterolhepatic steatosisproprotein convertase subtilisin kexin type 9receptorsecond-generation antipsychotic drugstriglyceride

Substanzen

OlanzapinePCSK9 protein, humanProprotein Convertase 9TriglyceridesCholesterolLipids

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Stomatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Medicine, Columbia University Medical Center, New York, New York, USA.

ORCID-Profile: Piaopiao Huang, Juanli Ran, Wenqiang Zhu, Wen Dai, Yaxin Tang, Pingan Lian, Xiansheng Huang, Rong Li

Förderung

  • National Natural Science Foundation
  • Natural Science Foundation of Hunan Province
  • Chinese Cardiovascular Association-Access

Zitieren

APA

Huang, P., Ran, J., Zhu, W., Dai, W., Tang, Y., Lian, P., Huang, X., & Li, R. (2024). PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine‐induced hepatic steatosis via both receptor‐dependent and receptor‐independent pathways. The FASEB Journal. https://doi.org/10.1096/fj.202301748r

Vancouver

Huang P, Ran J, Zhu W, Dai W, Tang Y, Lian P, et al. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine‐induced hepatic steatosis via both receptor‐dependent and receptor‐independent pathways. The FASEB Journal. 2024. doi:10.1096/fj.202301748r

BibTeX
@article{Huang2024,
  author = {Huang, Piaopiao and Ran, Juanli and Zhu, Wenqiang and Dai, Wen and Tang, Yaxin and Lian, Pingan and Huang, Xiansheng and Li, Rong},
  title = {PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine‐induced hepatic steatosis via both receptor‐dependent and receptor‐independent pathways},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202301748r}
}
Kostenlos starten →